Imagine what it means to give leukemia patients hope
Researchers at CU Anschutz’s Gates Institute are exploring early use of a last-resort therapy in patients with an aggressive form of leukemia.
The groundbreaking phase I clinical trial of CAR T-cell therapy is made possible through gifts for health and health care transformations, which totaled $245 million in 2023. Notably, the Gates Frontiers Fund fueled the institute through philanthropic investments, which are expected to grow to $200 million over the next five years. Philanthropy ensures essential cancer research of this magnitude remains in reach.